Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Mancang Gu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3782-0988; OpenAlex author ID A5103188059. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
46
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: 3 papers · 2024: 3 papers · 2025: 1 paper · 2026: 1 paper

Papers 16

  1. Coixenolide Enhances Antitumor Immunity of Cytotoxic CD8+ T Cells by Inhibiting S100A8/A9-CD36 Axis in Obesity-Associated Pancreatic Adenocarcinoma. Last author DOI 10.1002/advs.202515759↗
  2. Glutathione S-transferase Theta 2 causes drug resistance by inhibiting arsenic trioxide-induced ferroptosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.freeradbiomed.2025.06.053↗
  3. Corrections to: “The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super‐enhancer activity and the PI3K/AKT/mTOR signall… Co-author DOI 10.1002/ctm2.70158↗
  4. Albumin conjugation promotes arsenic trioxide transport through alkaline phosphatase-associated transcytosis in MUC4 wildtype pancreatic cancer cells. Last author DOI 10.1016/j.ijbiomac.2023.128756↗
  5. Integration of caveolin-mediated cytosolic delivery and enzyme-responsive releasing of squalenoyl nanoparticles enhance the anti-cancer efficacy of chidamide i… Last author DOI 10.1016/j.ijpharm.2024.124072↗
  6. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic… Co-author DOI 10.1002/ctm2.1500↗
  7. Acute toxicities of intravenous, intraperitoneal, or intratumoral injection of natural killer cells in human pancreatic adenocarcinoma-bearing mice: Randomized… Co-author DOI 10.1016/j.intimp.2023.110881↗
  8. A Three-Dimensional Technique for The Visualization of Mitochondrial Ultrastructural Changes in Pancreatic Cancer Cells. Last author DOI 10.3791/65290↗
  9. Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling. Last author DOI 10.1016/j.phymed.2021.153537↗
  10. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  11. Coix Seed Extract Enhances the Anti-Pancreatic Cancer Efficacy of Gemcitabine through Regulating ABCB1- and ABCG2-Mediated Drug Efflux: A Bioluminescent Pharma… Last author DOI 10.3390/ijms20215250↗
  12. UPLC‑MS/MS‑based metabolomic characterization and comparison of pancreatic adenocarcinoma tissues using formalin‑fixed, paraffin‑embedded and optimal cutting t… Last author DOI 10.3892/ijo.2019.4898↗
  13. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  14. Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells. First author DOI 10.1097/cad.0000000000000315↗
  15. Coix seed emulsion synergistically enhances the antitumor activity of gemcitabine in pancreatic cancer through abrogation of NF-κB signaling. Last author DOI 10.3892/or.2016.4958↗
  16. Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells. Co-author DOI 10.1007/s10637-013-9987-y↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kaidi Chen · 6 shared papers, 2023–2026 · strength 1.22
  2. Yuwei Qi · 5 shared papers, 2023–2026 · strength 1.01
  3. Lei Huang · 4 shared papers, 2023–2026 · strength 0.86
  4. Rong Chen · 3 shared papers, 2024–2026 · strength 0.60
  5. Wei Shan Li · 3 shared papers, 2024–2025 · strength 0.58
  6. Junyan Chen · 3 shared papers, 2024–2025 · strength 0.58
  7. Yan Xia Shi · 4 shared papers, 2018–2024 · strength 0.56
  8. Guanghai Dai · 2 shared papers, 2023–2024 · strength 0.42
  9. Yifan Qian · 3 shared papers, 2019–2021 · strength 0.32
  10. Yan Shi · 1 shared paper, 2023 · strength 0.22
  11. Di Feng · 2 shared papers, 2019–2021 · strength 0.21
  12. Yafang Qian · 2 shared papers, 2016–2021 · strength 0.20
  13. Yan Zhang · 1 shared paper, 2024 · strength 0.18
  14. Liping Chen · 1 shared paper, 2021 · strength 0.12
  15. David C. Linehan · 2 shared papers, 2018–2019 · strength 0.11
  16. Albert C. Koong · 2 shared papers, 2018–2019 · strength 0.11
  17. Chen Yuan · 2 shared papers, 2018–2019 · strength 0.11
  18. Richard Francis Dunne · 2 shared papers, 2018–2019 · strength 0.11
  19. Andrea J. Bullock · 2 shared papers, 2018–2019 · strength 0.11
  20. Thomas E. Clancy · 2 shared papers, 2018–2019 · strength 0.11
  21. Atsuhiro Masuda · 2 shared papers, 2018–2019 · strength 0.11
  22. Douglas Adam Rubinson · 2 shared papers, 2018–2019 · strength 0.11
  23. Vicente Morales‐Oyarvide · 2 shared papers, 2018–2019 · strength 0.11
  24. Margaret M. Kozak · 2 shared papers, 2018–2019 · strength 0.11
  25. Zhi Rong Qian · 2 shared papers, 2018–2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.